A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy
Key facts
- Who runs it
- Shanghai Jiaolian Drug Research and Development Co., Ltd
- Where
- China5 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 52 people, planned
- Started
- 2 Mar 2023
- Expected to end
- 30 Dec 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- B007
- Record updated
- 30 April 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Subjects who have fully understood this study and voluntarily signed the informed consent form
- Male or female subjects, aged between 18 and 75 years
- Subjects with primary membranous nephropathy pathologically confirmed by renal biopsy
- Subjects with systolic blood pressure ≤ 140 mmHg and diastolic blood pressure ≤ 90 mmHg at screening
- If taking ACEI(Angiotensin converting enzyme inhibitors), ARB(Angiotensin receptor blocker), a stable dose within 4 weeks before screening is required
- Subjects who are able to follow the study protocol as judged by the investigator
Who cannot take part
- Subjects with uncontrolled blood pressure as judged by the investigator within 3 months before screening
- Subjects with decreases in urine protein ≥ 50% within 6 months before screening
- Subjects who have received or are receiving renal replacement therapy
- Subjects who have a clear history of tuberculosis or have received anti-tuberculosis treatment
- Subjects who received live vaccination, major surgery, or participated in other clinical trials within 28 days before receiving the study drug
- Pregnant or lactating women; women of childbearing potential who have not been sterilized do not agree to use appropriate contraceptive measures during treatment and for at least 12 months after the last dose of the study drug
- Subjects with type 1 diabetes mellitus, or those with type 2 diabetes mellitus who are diagnosed as diabetic nephropathy by percutaneous renal biopsy
- Subjects with active bacterial, viral, fungal, mycobacterial, parasitic or other infections requiring systemic antibiotics or antiviral therapy
- Subjects with known history of severe allergic reactions to humanized monoclonal antibodies;
- Subjects with serious, progressive, or uncontrolled disease that may increase risks during the participation in the study as assessed by the investigator
- Subjects with a history of alcoholism or drug abuse within 12 months
- Subjects with positive hepatitis B surface antigen; those with positive hepatitis C virus antibody; those with a history of immunodeficiency
- Other conditions unsuitable for participation in this study determined by the Investigator
- Subjects with CD4+ T lymphocyte count < 300 cells/μL
- Subjects with secondary membranous nephropathy
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This Phase I Clinical Study assessed the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy
The 3 groups in the trial
- B007:350mgTreatment being tested
B007:350mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
Treatment: B007
- B007:700mgTreatment being tested
B007: 700mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
Treatment: B007
- B007:1000mgTreatment being tested
B007: 1000mg Subcutaneous injection was administered on days 1 and 15 B007 matched Placebo Subcutaneous injection was administered on days 1 and 15
Treatment: B007
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles and Preliminary Efficacy of Subcutaneous Injection of Recombinant Humanized Anti-CD20 Monoclonal Antibody in the Treatment of Primary Membranous Nephropathy
- Criteria questions
- Built from NCT05668403, who can take part
- Record updated
- 30 April 2026